New injection could spare cancer patients from repeated belly drains
NCT ID NCT06432296
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a drug called M701, given as an injection into the belly, to see if it can reduce the need for draining fluid in people with malignant ascites from advanced stomach, colorectal, or ovarian cancer. About 312 participants will either receive M701 plus drainage or drainage alone. The main goal is to see how long it takes before another drainage is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M701 (a bispecific antibody targeting EpCAM and CD3)
What this could lead to
If successful, this could provide a new way to control malignant ascites, reducing the need for frequent fluid drainage and improving quality of life.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The drug may not significantly delay fluid buildup or improve survival, and there may be side effects from the intraperitoneal injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
The First Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100141, China